Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

Viz.ai is teaming up with Cortechs.ai to integrate Cortechs.ai’s NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, thus expanding access to quantitative neuroimaging for U.S. hospitals and health systems.

This partnership marks Viz.ai’s expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai’s care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale.

“Viz.ai’s core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care team member, at the right time, to improve patient outcomes,” Viz.ai Chief Medical Officer Dr. Tim Showalter said. “This collaboration with Cortechs.ai extends that commitment into neurodegenerative disease, an area with profound unmet need and enormous potential—particularly where earlier patient identification and disease characterization can meaningfully change the treatment trajectory. We see this as the foundation for something much bigger, and we’re just getting started.”

With an established footprint of nearly 2,000 U.S. hospitals, Viz.ai claims it is positioned alongside Cortechs.ai to ensure patients with neurodegenerative disease reach the right care, faster.

“Cortechs.ai is building NeuroQuant into the leading platform for neuro quantification and analysis by providing the trusted intelligence layer that enables healthcare innovators to seamlessly integrate clinically validated quantitative imaging into their own solutions,” Cortechs.ai CEO Kyle Frye stated. “We believe the future of healthcare AI will be built on connected platforms, not isolated point solutions. Our partnership with Viz.ai is a powerful example of that vision, combining Viz.ai’s care coordination platform with the trusted quantitative insights of NeuroQuant and NeuroQuant MS platforms to accelerate innovation, enhance clinical decision-making, and ultimately improve outcomes for patients.”

Viz.ai offers AI-powered care coordination and clinical workflow solutions, deployed in nearly 2,000 U.S. hospitals and trusted by life sciences companies. Its platform combines real-time, multimodal clinical data with deep clinician engagement to detect disease earlier, coordinate care teams, and help ensure patients receive the right treatment faster. Viz.ai was the first company to be awarded CMS reimbursement for AI and is ranked the top Healthcare AI Platform by hospitals and health systems in the Black Book Research survey.

Cortechs.ai brands itself as a leader in AI applications in radiology. Cortechs.ai uses cutting-edge technologies in medical imaging to revolutionize disease screening and early detection. The company develops and markets breakthrough medical device software that quantifies and tracks neurodegenerative diseases and helps detect clinically significant cancer. Cortechs.ai’s brain imaging software provides radiologists, neurologists, oncologists, and clinical researchers worldwide with a convenient and cost-effective way to quantify brain structures for assessing Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and other brain abnormalities. The company’s numerous U.S. Food and Drug Administration-cleared products provide quantitative insights to help physicians with the diagnosis and follow-up of neurodegenerative and traumatic brain conditions, as well as prostate cancer.